



# UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE  
United States Patent and Trademark Office  
Address: COMMISSIONER FOR PATENTS  
P.O. Box 1450  
Alexandria, Virginia 22313-1450  
www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
09/829,922	04/11/2001	Thanos Halazonetis	02973.00031	1142

22907 7590 12/23/2003

BANNER & WITCOFF  
1001 G STREET N W  
SUITE 1100  
WASHINGTON, DC 20001

EXAMINER

HUFF, SHEELA JITENDRA

ART UNIT PAPER NUMBER

1642

DATE MAILED: 12/23/2003

Please find below and/or attached an Office communication concerning this application or proceeding.

## Office Action Summary

Application No.

09/829,922

Applicant(s)

HALAZONETIS ET AL.

Examiner

Sheela J Huff

Art Unit

1642

-- The MAILING DATE of this communication appears on the cover sheet with the correspondence address --

### Period for Reply

A SHORTENED STATUTORY PERIOD FOR REPLY IS SET TO EXPIRE 3 MONTH(S) FROM THE MAILING DATE OF THIS COMMUNICATION.

- Extensions of time may be available under the provisions of 37 CFR 1.136(a). In no event, however, may a reply be timely filed after SIX (6) MONTHS from the mailing date of this communication.
- If the period for reply specified above is less than thirty (30) days, a reply within the statutory minimum of thirty (30) days will be considered timely.
- If NO period for reply is specified above, the maximum statutory period will apply and will expire SIX (6) MONTHS from the mailing date of this communication.
- Failure to reply within the set or extended period for reply will, by statute, cause the application to become ABANDONED (35 U.S.C. § 133).
- Any reply received by the Office later than three months after the mailing date of this communication, even if timely filed, may reduce any earned patent term adjustment. See 37 CFR 1.704(b).

### Status

- 1) ☒ Responsive to communication(s) filed on 04 December 2003.
- 2a) ☒ This action is **FINAL**. 2b) ☐ This action is non-final.
- 3) ☐ Since this application is in condition for allowance except for formal matters, prosecution as to the merits is closed in accordance with the practice under *Ex parte Quayle*, 1935 C.D. 11, 453 O.G. 213.

### Disposition of Claims

- 4) ☒ Claim(s) 23-29 is/are pending in the application.
- 4a) Of the above claim(s) ~~23-29~~ is/are withdrawn from consideration.
- 5) ☐ Claim(s) \_\_\_\_\_ is/are allowed.
- 6) ☒ Claim(s) 23-29 is/are rejected.
- 7) ☐ Claim(s) \_\_\_\_\_ is/are objected to.
- 8) ☐ Claim(s) \_\_\_\_\_ are subject to restriction and/or election requirement.

### Application Papers

- 9) ☐ The specification is objected to by the Examiner.
- 10) ☐ The drawing(s) filed on \_\_\_\_\_ is/are: a) ☐ accepted or b) ☐ objected to by the Examiner.  
Applicant may not request that any objection to the drawing(s) be held in abeyance. See 37 CFR 1.85(a).  
Replacement drawing sheet(s) including the correction is required if the drawing(s) is objected to. See 37 CFR 1.121(d).
- 11) ☐ The oath or declaration is objected to by the Examiner. Note the attached Office Action or form PTO-152.

### Priority under 35 U.S.C. §§ 119 and 120

- 12) ☐ Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f).  
a) ☐ All b) ☐ Some \* c) ☐ None of:  
1. ☐ Certified copies of the priority documents have been received.  
2. ☐ Certified copies of the priority documents have been received in Application No. \_\_\_\_\_.  
3. ☐ Copies of the certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)).  
\* See the attached detailed Office action for a list of the certified copies not received.
- 13) ☐ Acknowledgment is made of a claim for domestic priority under 35 U.S.C. § 119(e) (to a provisional application) since a specific reference was included in the first sentence of the specification or in an Application Data Sheet. 37 CFR 1.78.  
a) ☐ The translation of the foreign language provisional application has been received.
- 14) ☐ Acknowledgment is made of a claim for domestic priority under 35 U.S.C. §§ 120 and/or 121 since a specific reference was included in the first sentence of the specification or in an Application Data Sheet. 37 CFR 1.78.

### Attachment(s)

- 1) ☐ Notice of References Cited (PTO-892)
- 2) ☐ Notice of Draftsperson's Patent Drawing Review (PTO-948)
- 3) ☐ Information Disclosure Statement(s) (PTO-1449) Paper No(s) \_\_\_\_\_
- 4) ☐ Interview Summary (PTO-413) Paper No(s) \_\_\_\_\_
- 5) ☐ Notice of Informal Patent Application (PTO-152)
- 6) ☐ Other: \_\_\_\_\_

## ***DETAILED ACTION***

### ***Response to Amendment***

The amendment filed on 12/4/03 has been considered. Applicant's arguments are deemed to be persuasive-in-part.

Claims 23-29 are pending.

### ***Amendment***

The amendment filed on 12/4/03 has not met all of the requirement of 37 CFR 1.121, as amended on June 30, 2003 (see 68 Fed. Reg. 38611, Jun 30, 2003). The amendment did not provide a complete listing of all of the claims. While applicant does not need to re-submit this amendment, applicant must fully comply with the above in the future.

### ***Response to Arguments***

### ***Claim Rejections - 35 USC § 112***

Claims 23-26 remain rejected under 35 U.S.C. 112, first paragraph, as failing to comply with the enablement requirement. The claim(s) contains subject matter which was not described in the specification in such a way as to enable one skilled in the art to which it pertains, or with which it is most nearly connected, to make and/or use the invention. The reasons for this rejection are of record in the action mailed 6/4/03.

Applicant argues that clinical data is not needed. This is true and clinical data is not what the Examiner is asking for. The Examiner stated that there is no correlation between the in vitro assays used in the specification and the treatment of any of the multitude of claimed disorders. Applicant points to Example 5 for enablement. This is an in vitro assay and there is no objective evidence of record to show that it is known in

the art that a compound successful in this assay will lead to a treatment of any of the claimed conditions. As stated in MPEP 2164.02 under "CORRELATION: *IN VITRO/IN VIVO*", there needs to be a correlation between in vitro and in vivo for the working example to be construed as a proper working example. "If there is no correlation, then the examples do not constitute "working examples". Thus, because there is no correlation (at least no objective evidence of record to show that correlation exists), the working examples are not construed as "working examples" and applicant has not enabled his invention.

***Claim Rejections - 35 USC § 112***

Claims 27-29 are rejected under 35 U.S.C. 112, first paragraph, because the specification, while being enabling for the method of activating DNA binding in vitro, does not reasonably provide enablement for the method of activating DNA binding in vivo. The specification does not enable any person skilled in the art to which it pertains, or with which it is most nearly connected, to use the invention commensurate in scope with these claims.

Applicant claims are discloses a method of activating DNA binding of a p53 polypeptide. By using the terminology, this claims reads on both in vitro and in vivo administering. While applicant is enabled for the in vitro use, applicant is not enabled for the in vivo use. The claims are directed to in vivo uses and there is no correlation between in vitro use and in vivo use. In vivo uses are unpredictable because pharmacokinetic factors such as the stability of the peptides in the body, half-life, absorption efficiency, binding affinity for target cells, biotransformation, and the rate of clearance from the body are important considerations of the claimed subject matter and

Art Unit: 1642

yet have not been considered. In the absence of these considerations, there is no assurance (ie. it is unpredictable) that the active peptide would be available in effective doses at the target sites and for periods of time sufficient to effect the required cellular or biological responses.

The state of the art does not show that the in vitro assays used in vitro can readily be correlated to in vivo used by one skilled in the art. As stated in MPEP 2164.02 under "CORRELATION: *IN VITRO/IN VIVO*", there needs to be a correlation between in vitro and in vivo for the working example to be construed as a proper working example. "If there is no correlation, then the examples do not constitute "working examples". Thus, because there is no correlation (at least no objective evidence of record to show that correlation exists) , the working examples are not construed as "working examples" and applicant has not enabled his invention.

In view of the above, it is the Examiner's position that one skilled in the art could not make and/or use the invention without undue experimentation.

### ***Conclusion***

Applicant's amendment necessitated the new ground(s) of rejection presented in this Office action. Accordingly, **THIS ACTION IS MADE FINAL**. See MPEP § 706.07(a). Applicant is reminded of the extension of time policy as set forth in 37 CFR 1.136(a).

A shortened statutory period for reply to this final action is set to expire THREE MONTHS from the mailing date of this action. In the event a first reply is filed within TWO MONTHS of the mailing date of this final action and the advisory action is not mailed until after the end of the THREE-MONTH shortened statutory period, then the


Art Unit: 1642

shortened statutory period will expire on the date the advisory action is mailed, and any extension fee pursuant to 37 CFR 1.136(a) will be calculated from the mailing date of the advisory action. In no event, however, will the statutory period for reply expire later than SIX MONTHS from the date of this final action.

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Sheela J Huff whose telephone number is 703-305-7866. The examiner can normally be reached on Tuesday 5:30am-11:30am and Fridays 6:00am-4:00pm.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Anthony Caputa can be reached on 703-308-3995. The fax phone number for the organization where this application or proceeding is assigned is 703-308-4242.

Any inquiry of a general nature or relating to the status of this application or proceeding should be directed to the receptionist whose telephone number is 703-308-1235.

  
Sheela J Huff  
Primary Examiner  
Art Unit 1642

sjh